Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 495 - файл

.pdf
Скачиваний:
0
Добавлен:
29.08.2026
Размер:
31 Мб
Скачать
374
https://t.me/medicina_free
DYSPHAGIA ASSESSMENT AND TREATMENT PLANNING: A TEAM APPROACH
Tabl e 16 –2. Motor Neuron (MN) Diseases Subtypes and
Neurons Affected
Motor Neuron Disease Subtype Upper MN Lower MN
Amyotrophic lateral sclerosis Ye s Yes
Primary lateral sclerosis Yes No
Progressive muscular atrophy No Yes
Progressive bulbar palsy No Yes
Spinal muscular atrophy No Ye s
Postpolio syndrome No Yes
both timing and structural impair­ments may occur (and silent aspiration is prevalent), the DSS will be invaluable in guiding rehabilitative and compen­satory strategies and texture modifica­tions. DSS may also suggest the need for nonoral nutrition when swallow­ing safety is grossly compromised. Early assessment by videofluoroscopy should be considered in patients pre­senting with ALS even in the absence of reported dysphagia. Patients who demonstrate combined timing and structural abnormalities of unknown etiology on DSS should be referred for neurological assessment if this has not already been carried out.
Brain Injury
Prevalence of dysphagia following brain injury seems to vary but may affect 20% to 70% of patients (Kang et al., 2011; Rugiu, 2007; Takizawa et al.,
2016). Brain injury can occur as a result of targeted intervention (surgery or radiotherapy) or after trauma, vascular insult, or metabolic disorder. Traumatic brain injury (TBI) is commonly caused
by motor vehicle accidents, cycle acci­dents, or falls. It affects both children and adults. Of patients who have been mechanically ventilated following TBI, 65% failed bedside swallowing safety evaluations (BSEs). TBI increased the likelihood of failing a BSE by 3.2 times. The risk of failing a swallowing survey was increased further if the patient was elderly (>70) or had a tracheostomy (Brown et al., 2011).
Typically, onset of dysphagia is acute and recovery may occur following ini­tial injury, making reassessment vital in determining ongoing dietary recom­mendations and modifications (Kim & Suh, 2018). Swallowing impairments after TBI often involve the voluntary phases of deglutition and incoordina­tion of gestures. These are highlighted well using the DSS timing measures described in Chapters 6 to 8. Oropha­ryngeal deficits are also seen following TBI and may be accompanied by primi­tive reflexes (tongue pumping, sucking, tongue extrusion) (Rugiu, 2007).
In children, severe TBI causes a high rate of dysphagia (68%–76%) but rap­idly improves, usually over 3 months (Morgan, 2010). Given the prevalence
16. NEUROGENIC DYSPHAGIA
https://t.me/medicina_free
375
of traumatic brain injuries in children (listed as high as 280 per 100,000), there will be a significant number of children requiring both assessment and treat­ment for swallowing problems (Mor­gan, 2010). The inherent risks of radia­tion exposure from videofluoroscopy must be weighed against the invaluable information that can be gained from the study that might direct dietary modi­fications, swallowing rehabilitation, and removal of enteral feeding tubes or tracheostomies. Other factors that should be considered in children fol­lowing TBI are associated motor dis­orders, level of cognition (ability to appreciate their dysphagia), and pos­tural issues (Morgan, 2010). These may compound dysphagia and its manage­ment. In children, the DSS may show typical adult post-TBI findings such as tongue pumping, residue, bolus spill, or delayed swallow but may also dem­onstrate additional findings not seen in adults, such as primitive reflexes (suckle, tongue protrusions). In a pro­spective study of 18 children with TBI assessed by videofluoroscopy a month after injury, 17% (3/18) aspirated thirds silently (Morgan, 2010).
— two
Multiple Sclerosis
Multiple sclerosis (MS) is a progressive demyelinating, inflammatory disease that involves both central and periph­eral nerves (Sandrini & Nappi, 2008). Plaques form in nerve sheaths that result in significant conduction delays and eventual loss of function. As the number of plaques increases in the cen­tral nervous system, the likelihood of dysphagia increases, as the dominant swallow hemisphere is more likely
to be involved (Tassorelli et al., 2008). Lesions in the anterior insula or oper­cular area (including sensorimotor and premotor cortices) can be involved in the manifestation of swallow problems.
Dysphagia occurs in 24% to 43% of patients with MS but is much more common as disability increases (up to 80% in advanced disease) (Ansari et al., 2020; Danesh-Sani et al., 2013; González-Fernández et al., 2008; Printza et al., 2020; Rugiu, 2007; Tassorelli et al., 2008). Dysphagia is associated with longer disease duration, cerebellar involvement, and increasing disability (Calcagno et al., 2002; Danesh-Sani et al., 2013; Pooravid et al., 2010; Tassorelli et al., 2008). Calcagno and colleagues (2002) followed 143 MS patients using FEES and found that advanced disease and cerebellar involvement portended a higher rate of dysphagia. However, 17% of patients with milder disease also demonstrated dysphagia. This empha­sizes the need to screen, with videofluo­roscopy or FEES, patients suspected of aspiration, having pulmonary prob­lems, or with advanced disease.
The oral and pharyngeal phases of swallowing are often affected and UES dysfunction is reported frequently (100% of patients in one study) (Abra­ham et al. [in González-Fernández et al., 2008]; Rugiu, 2008; Tassorelli et al.,
2008). In a study of 23 MS patients, 40% were silent aspirators and more than 80% had some changes in either swal­low safety or efficiency as assessed by DSS (Terré-Boliart et al., 2004).
A further recent study of 101 MS patients using only a patient screening questionnaire (Northwestern Dyspha­gia Patient Check Sheet) demonstrated pharyngeal swallowing complaints in 30% and symptoms of aspiration in
376
https://t.me/medicina_free
DYSPHAGIA ASSESSMENT AND TREATMENT PLANNING: A TEAM APPROACH
7% of patients. In a study of 108 MS patients, Printza and colleagues found 26% of subjects complained of swal­lowing issues, 34% showed abnormal EAT-10 scores indicating dysphagia, and 44% were identified to have swal­lowing issues by the DYMUS (dyspha­gia in multiple sclerosis) questionnaire (Printza et al., 2020).
Bergamaschi and colleagues (2009) validated the DYMUS questionnaire for assessment of dysphagia in MS. This 10-item questionnaire is subdivided into two scales — dysphagia with sol­ids and dysphagia with liquids, both of which demonstrate good internal valid­ity and consistency (Alali et al., 2018). Each item is scored dichotomously (yes or no) and the survey may be completed within a few minutes, making the DYMUS a good screening tool for iden­tifying those patients needing instru­mental evaluation and dietary manage­ment. DYMUS has been translated into multiple languages and further vali­dated (Ansari et al., 2020). There is also a shortened five-item version of DYMUS wherein a single positive answer should trigger full swallow assessment, as well as modifications of the DYMUS ques­tionnaire to address other neurological disorders such as motor neuron disease (DYALS, see above).
Additional questionnaire-based tools have been developed such as the Dys­phagia Screening Questionnaire for multiple sclerosis (DSQMS). This is a five-question (with graded responses) tool and is self-reported by the patient. It may indicate swallowing problems but has not been fully validated as yet (Ansari et al., 2020).
A bedside assessment can be aug­mented by tasks for patients to com­plete such as in the Water Swallowing
Speed Test (WSST) wherein the patient swallows a set volume of fluid and is timed, allowing calculation of swal­low speed and volume. Previous work using this approach in MS patients reports high sensitivity in detecting swallow impairment (85.5% sensitiv­ity), but further reliability and valid­ity testing are needed in MS patients to understand the role of these tools (Ansari et al., 2020).
Instrumental evaluation is still cru­cial in fully understanding the swallow in MS patients given the rate of asymp­tomatic abnormalities. Both FEES and videofluoroscopy provide important swallowing information, and findings are often complementary. The videoflu­oroscopic evaluation is often selected as it allows dynamic assessment of oral, pharyngeal, and esophageal phases (Ansari et al., 2020) as well as identifica­tion of aspiration events. It also allows trials of food stuffs and pills where this may assist in management planning.
Cerebral Palsy
Cerebral palsy (CP) is a nonprogressive neurological motor and processing dis­order that arises following injury to the fetal or infant brain. Although thought of as a childhood disease, most people (>85%) with CP will now survive well into adulthood, particularly if there are no additional disabilities present (Haak et al., 2009). CP presents disorders of communication and deglutition, as well as cognition, sensation, and behavior. Swallowing problems in CP can be both sensory and motor in nature. Spasticity that accompanies the musculoskeletal changes of CP may result in disordered swallow, unusual posturing, difficulty
16. NEUROGENIC DYSPHAGIA
https://t.me/medicina_free
377
transferring food and fluids to the oral cavity, and penetration or aspira­tion (Haak et al., 2009). The estimated prevalences of drooling, swallowing problems, and feeding issues are 44%,
50.4%, and 53.5%, respectively (Speyer et al., 2019). Cough with food or fluids and choking episodes, as well as silent aspiration, have been described in CP patients (Rogers et al., 1994). Severity of the disorder is related to presence of other disabilities and gross motor function (Speyer et al., 2019). Rog­ers et al. (1994) demonstrated marked abnormalities of deglutition on DSS in 86 children with CP and concomitant other disabilities: 93% of children were nonambulatory, 90% were mentally retarded, and 29% had gastrostomies placed for feeding. Benfer and col­leagues compared children with CP in Australia and Bangladesh (n = 211) and identified oropharyngeal dysphagia in 55% and 68%, respectively (nonsignifi­cant difference when stratified for gross motor function) (Benfer et al., 2017). In patients in whom CP is the only dis­order present, swallowing may be far more functional (Haak et al., 2009).
In adults with CP, swallow abnor­malities are prevalent. Seo et al. (2019) studied 17 adults with dyskinetic CP and cervical dystonia by videofluoros­copy. They found approximately 60% of subjects demonstrated abnormal chewing and oral control, inadequate mastication of bolus, premature spill of bolus, vallecular residue, and pen­etration and aspiration. In this group, silent aspiration was identified in 47%. Swallowing parameters did not corre­late with observed gross motor function classification (Seo et al., 2019). These findings highlight the critical role of an instrumental assessment in holistically
assessing swallowing features in CP patients. DSS will identify which aspect of swallowing is affected and direct therapy. Due to global musculoskeletal problems, positioning during DSS may be difficult and may need to be altered.
Dementia — Alzheimer’s Disease
Dementia is characterized by an over­all decline in intellectual function and memory. Motor skills, particularly se­quenced activity, are also affected. The population affected by any form of dementia is predicted to triple by 2050 (Espinosa-Val et al., 2020). Multi-infarct dementia is due to repeated vascular insults. Alzheimer’s disease (the most common form of dementia) is produced by deposition of protein that impairs neural function. Other forms of demen­tia may be associated with particular disorders — for example, Huntington’s chorea and Pick’s disease. Medications (particularly polypharmacy seen in the elderly) and use of drugs and alcohol can all cause dementia and cognitive decline.
Swallowing problems are common in dementia. One third of Alzheimer’s disease sufferers may aspirate (on videofluoroscopy), and pneumonia is the most common cause of death in this population (González-Fernández etal., 2008; Pizzorni et al., 2020). Poor cognition, poor memory, and inability to feed oneself also contribute to eat­ing dysfunction. A recent longitudinal study following 255 patients diagnosed with dementia reported a prevalence of oropharyngeal swallow dysfunc­tion of 86% (Espinosa-Val et al., 2020). A study of the inherited dementia, Huntington’s disease, demonstrated
378
https://t.me/medicina_free
DYSPHAGIA ASSESSMENT AND TREATMENT PLANNING: A TEAM APPROACH
high prevalence of swallow impair­ment, even early in the disease, includ­ing silent aspiration, and recommended instrumental assessments in this group (Pizzorni etal., 2020). De Stefano and colleagues retrospectively assessed 52patients with mild cognitive decline or dementia and swallowing issues. Assessment included mealtime obser­vation, FEES, Mini Mental State Exam (MMSE), MD Anderson Dysphagia Inventory (MDADI), and caregiver mealtime and dysphagia questionnaire (De Stefano etal., 2020). Clinician eval­uations categorized 97% of patients as having swallow impairment, whereas the MDADI alone classified only 23% of cases and the caregiver questionnaire estimated only 54% of subjects to have abnormal swallowing. This suggests that instrumental evaluation is needed to correctly assess swallow ability (De Stefano et al., 2020).
Oral and oropharyngeal dysfunction occur with dementia and can be seen on DSS. Delayed airway closure predicts unsafe swallows in demented adults (Espinosa-Val et al., 2020). Laryngeal deficits such as poor vocal fold mobil­ity, weak cough, and prolonged swal­low gestures increase the likelihood that mismanagement of the bolus will result in airway violation. Institution­alization also impacts on diet and mor­tality, as does oral hygiene in these patients. A recent study of hospitalized patients with dementia across New York State found that 42% of patients demonstrated swallowing problems and that dysphagia was associated with delirium, increased length of stay, and mortality (odds ratio = 4.44) (Makhnev­ich et al., 2022). In a quasi-randomized observational study of senile dementia patients, fluoroscopy was used to assess
improvement of swallow parameters in the pharynx and esophagus after swal­lowing therapy with or without Men­delsohn’s maneuver. Improved VFSS scores were seen in those that received swallow training at 15 and 30 days after training, indicating that despite demen­tia, these patients may benefit from swallow therapy (Zhang et al., 2021).
Further research in those suffering with forms of dementia or Alzheimer’s disease is needed to understand dys­phagia progression and effective man­agement strategies. Swallowing safety may be the most important aspect assessed by DSS, and it may also guide therapeutic options. Teaching rehabilita­tive strategies may still be valid in some groups despite poor memory function and with help of caregiver input.
Medication Effects
Many medications have a detrimental effect on swallowing. Medication can cause clouding of mentation, extrapyra­midal effects (mimicking parkinsonian features), and delayed neuromuscular responses. Medications are also known to reduce lower esophageal sphincter pressures, promoting reflux and wors­ening dysmotility (Tutuian, 2010) and cause xerostomia. Many elderly indi­viduals are on multiple medications, thus experiencing compounding drug effects (Ney et al., 2009). Polypharmacy is particularly problematic in generat­ing xerostomia and should be consid­ered whenever a new medication is added to existing therapy.
Many classes of common medications cause dryness, including antihistamines, diuretics, anticholinergic medications for pain and mood, alpha-blockers for
16. NEUROGENIC DYSPHAGIA
https://t.me/medicina_free
379
prostatism, and analgesics. Compen­sations may be required, for example, additional voluntary hydration tech­niques or reducing doses of competi­tive or synergistic medications. Medi­cations may also cause idiosyncratic (or unpredictable) side effects, including swallow problems such as bisphospho­nates. New monoclonal antibodies such as pembrolizumab have been shown to cause progressive dysphagia in rare patients (Reynolds & Guidon, 2019). A physician should be involved in med­ication reconciliation when needed. DSS will enable evaluation of motility and most stricture sites and can some­times suggest dryness when adherent diffuse coating of barium is seen over the tongue dorsum and valleculae.
Pill esophagitis is not uncommon in the elderly, generated by swallowing several pills at once, where salivary flow is decreased and in individuals in whom swallowing problems are more prevalent due to coexistent pathology. Pills lodged in the upper esophagus can cause serious ulceration and dis­comfort. Large tablets or capsules may be particularly difficult to swallow, and reformulation of medications to liquids can improve swallowing safety. Modi­fying formulations of medications (to liquids, suspensions, or dividing the pill) can be a crucial way to handle large pills, as can use of alternate vehicles to assist in pill swallowing (such as yogurt rather than water), which may help to transmit difficult-to-swallow medica­tions. Care must be taken to ascertain which medications are amenable to crushing/breaking so that pill effective­ness is not impaired.
Testing a pill during the DSS is a vital part of assessment for pill swallow­ing safety. Barium capsules of 13mm
diameter are available and can be administered at the time of esophageal screening, allowing the fluoroscopist to follow the passage of the pill from the oral cavity to the stomach. This also mimics the patients taking their regular medication and may demonstrate the difficulties that they are experiencing. Swallowing of a 13-mm barium tablet as part of the DSS protocol (anterior­posterior view) helps identify subtle esophageal irregularities not detected with liquid boluses such as strictures. Once the esophageal lumen is reduced below 13 mm, solid food dysphagia may occur. These effects will impact swallowing of all texture types.
PERIPHERAL NEUROMUSCULAR DISORDERS
Neuromuscular disorders may directly affect the muscle or innervation to the muscle (i.e., the neuromuscular unit). This section considers disorders affect­ing peripheral neuromuscular function rather than central dysfunction (such as CVA, MS, or Guillain-Barré syndrome).
Inflammatory Myositis — Polymyositis, Dermatomyositis, Inclusion Body Myositis, and Immune-Mediated Necrotizing Myopathy
The inflammatory myopathies include polymyositis (PM), dermatomyositis (DM), necrotizing autoimmune myosi­tis (NAM), and inclusion body myositis (IBM) and are due to infiltration of skele­tal muscle by inflammatory cells (B cells predominant in DM, T cells predomi­nant in PM and IBM) and deposition
380
https://t.me/medicina_free
DYSPHAGIA ASSESSMENT AND TREATMENT PLANNING: A TEAM APPROACH
of abnormal protein within muscle compartments (Ebert, 2009; Mastaglia, 2008; Naddaf et al., 2018).
Inclusion body myositis, IBM, is the most common acquired myopathy in adults and is progressive, with dys­phagia being a major symptom and often responsible for significant mor­bidity and mortality (Naddaf et al., 2018; Stathopoulos & Dalakas, 2022). IBM affects smaller peripheral muscle groups (Ebert, 2009; Mastaglia, 2008) and often affects quadriceps, finger flexors, and facial and swallowing muscles (Naddaf et al., 2018; Statho­poulos & Dalakas, 2022). Most cases are idiopathic, but there appears to be a genetic predisposition in IBM related to the HLA-DRB1 allele, and the degen­erative aspect of the disease has been associated with missense gene variants (Naddaf et al., 2018).
Immune-mediated necrotizing my­opathy, NAM, has emerged as the most common inflammatory myopathy in all age groups with acute onset in days or weeks and then a slow subacute phase that progresses to severe muscle weak­ness, including swallowing impair­ment. NAM is associated with ele­vated CK levels and antibodies against signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) (Stathopoulos & Dalakas, 2022).
Proximal musculature is primar­ily affected in polymyositis (PM) and dermatomyositis (DM). Reflux treat­ment with proton-pump inhibitors has been associated with cases of PM (Ebert, 2009). Dysphagia may also be associated with increased risk of can­cer in myopathy patients
— particularly in dermatomyositis, where 15% of DM patients have an underlying malig-
nancy and may express raised anti­NXP2 antibodies (Moghadam-Kia et al., 2020; Stathopoulos & Dalakas, 2022). However, the pathogenesis of DM and PM is still unclear.
Overall, inflammatory myopathy may present with dysphagia in 25% to 80% of patients, and during the course of disease, more than 60% of those with inflammatory myopathies experience some dysphagia (Langdon et al., 2012; Mulcahy et al., 2012; Williams et al.,
2003). Williams et al. (2003) reported radiographic abnormalities in 69% of 13 myositis patients studied. During vid­eofluoroscopy, 8 of 13 aspirated and 9 of 13 had an obstructive PES. Approxi­mately half of myositis patients also demonstrate pharyngeal weakness on manometry (Langdon et al., 2011; Wil­liams et al., 2003). Mulcahy et al. (2012) studied 18 patients with inflammatory myopathy and found overall, 78% of patients had abnormalities on video­fluoroscopy, including all of those with IBM (n = 8). Azola et al. (2020) studied 23 myositis patients with VFSS and demonstrated significantly shorter duration of airway closure and UES opening compared to healthy subjects. Cox et al. (2009) studied 43 patients with IBM and 79% showed abnormal fluoroscopic swallows. Fluoroscopy exhibits abnormal pharyngeal propul­sion in > 75% of IBM patients, with residue in the pharynx and impaired cricopharyngeal function (Stathopou­los & Dalakas, 2022). Upper esophageal sphincter opening was significantly reduced compared with neurogenic controls and age-matched healthy con­trols in a study by Williams et al. (2003). This was demonstrated well on video­fluoroscopy, as was aspiration in those affected patients. Aspiration was seen
in 20% of 15 IBM patients and CP dys-
https://t.me/medicina_free
function seen in 37% to 47% in other studies (Stathopoulos & Dalakas, 2022). Cox et al. (2009) also found that 37% of patients with inflammatory myositis demonstrated UES dysfunction, with 8 of 43 demonstrating a diverticulum.
Other DSS findings separating myo­sitis from central neurological disor­ders have been debated. Williams et al. (2003) found that there was pres­ervation of normal timing sequences and pharyngeal transit times in their cohort of 13 patients, while Ebert (2009) reported prolonged pharyngeal transit times. Pooling of bolus in the piriform fossae, reduced tongue base excur­sion, repeated swallows, and impaired hyolaryngeal elevation have also been described on DSS performed in those suffering from inflammatory myopa­thy, especially IBM, and dysphagia may be the initial presenting symptom in IBM patients (Cox et al., 2009; Langdon et al., 2012; Mulcahy et al., 2012; Statho­poulos & Dalakas, 2022). When there is prolonged outlet obstruction at the PES, the proximal pharynx may respond in a number of ways
— increased muscle effort, pharyngeal dilatation, or “blow out” with formation of a hypopharyn­geal diverticulum (Cox et al., 2009; Mulcahy et al., 2011; Williams et al.,
2003). Pharyngeal dilatation can be measured on DSS with the pharyngeal constriction ratio (PCR), and a diver­ticulum is readily diagnosed on fluo­roscopy (Figure 16–1).
The diagnosis of inflammatory myop­athy can be difficult and requires mus­cle biopsy, often leading to significant diagnostic delay (>4 years). As dys­phagia may be the initial presenting symptom, DSS may provide vital clues to diagnosis in this group of patients
16. NEUROGENIC DYSPHAGIA
Figure 16–1. Lateral videofluoroscopic view
of pharynx mid bolus outlining a moderately obstructive cricopharyngeal bar and elevated pha­ryngeal constriction ratio in a patient with inclusion body myositis.
swallow demonstrating
and swallowing clinicians may be the first to raise the possibility of the diagnosis. In a series of 529 cases of oropharyngeal dysphagia reported by Williams et al. (2003), only 5.7% were attributed to myopathy. Although they are a small patient group, treatment of the underlying disorder may improve muscle function and assist in resolution of dysphagic symptoms, and therefore this diagnosis should be considered in all patients with unexplained oropha­ryngeal dysphagia.
IBM remains refractory to current anti-inflammatory treatments that as­sist in other myopathies (such as cor­ticosteroids, azathioprine, methotrex­ate, and intravenous immunoglobulin [IVIG]), possibly due to the degenera­tive component, and therefore, treat­ment may need to be symptomatic.
381
382
https://t.me/medicina_free
DYSPHAGIA ASSESSMENT AND TREATMENT PLANNING: A TEAM APPROACH
However, IBM patients often respond very well to direct treatment of the UES such as cricopharyngeal dilation or myotomy (Naddaf et al., 2018; Wil­liams et al., 2003).
Muscular Dystrophies
Dystrophies are a disparate group of inherited diseases directly affecting muscle function with weakness of the affected muscle group and progres­sive fibrosis within the muscle. Often presenting in early childhood or at birth, the clinical course can be severe depending on subtype. Duchenne MD, Becker MD, myotonic MD, oculopha­ryngeal MD (OPMD), facioscapulo­humeral dystrophy (FSHD), and spinal muscular atrophy (SMA) are all associ­ated with swallowing impairments.
Duchenne Muscular Dystrophy (DMD)
DMD, the most common muscular dystrophy, is a lethal X-linked reces­sive, inherited neuromuscular disease wherein the genetic defect prevents the production of the normal muscle protein, dystrophin, that is crucial to myofiber structure. At least one third of DMD patients complain of dysphagia, which may be progressive; however, the prevalence of dysphagia in this patient group is likely underestimated (Birnkrant et al., 2018; Toussaint et al.,
2016). Treatment primarily requires high-dose glucocorticoids, which leads to nutritional abnormalities and can promote gastroesophageal reflux com­pounding pharyngeal muscle weakness (Birnkrant et al., 2018).
DMD sufferers demonstrate oral and pharyngeal phase muscle weak­ness leading to poor bolus control, pharyngeal residue, and postswallow penetration and aspiration (González­Fernández et al., 2008; Toussaint et al., 2016). They also show decreased tongue pressures impairing oral con­trol (Hamanaka-Kondoh et al., 2014). Choking may become more common with age, and dietary modifications are often implemented to make swallowing easier. PES opening and hyoid displace­ment are typically normal. Respiratory muscle weakness may contribute to poor lung clearance, making aspiration more significant in these patients, and should be an indication for early DSS assessment. Poor swallowing metrics correlate with respiratory measures, and as respiratory problems worsen, there is likely difficulty in the breathe­swallow coordination that promotes choking or misdirection of bolus.
Oculopharyngeal Muscular Dystrophy
Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset, progressive, genetic degenerative muscular dystro­phy resulting in ptosis, limb weakness, and dysphagia. Abnormal expansion of alanine-encoding trinucleotide repeats in the poly-adenosine binding protein nuclear 1 (PABPN1) gene is the primary cause (Yamashita, 2021). Diagnosis is through genetic testing (DNA sequenc­ing) and muscle biopsy/EMG testing to rule out other neuromuscular disor­ders. Recent findings of consistent fatty replacement of target muscles (tongue, pharyngeal constrictors, thigh adduc­tor, hamstring) on MRI offer a potential
16. NEUROGENIC DYSPHAGIA
https://t.me/medicina_free
383
new noninvasive diagnostic method, and tongue fatty infiltrate correlated with worse swallowing parameters (Melkus et al., 2022; Yamashita, 2021).
Patients with OPMD may compen­sate for ptosis by neck extension, which can compound swallowing difficulty. Patients experience prolonged meal­times and solid and dry food dyspha­gia followed by liquid dysphagia as the disease progresses (Manjaly et al., 2011; Yamashita, 2021).
Videofluoroscopic examination plays an important role in assessment and sur­veillance of OPMD. DSS will identify poor tongue base retraction, reduced pharyngeal constriction (96%), incom­plete airway closure, hyoid kinematic changes, UES dysfunction (45%), residue (77%–90%), and pharyngeal changes due to prolonged outlet obstruction (Tabor et al., 2018; Waito et al., 2018). In a study of 48 OPMD patients utiliz­ing VFSS, all showed abnormal resi­due in the pharynx and 19% aspirated (Kroon et al., 2020). Furthermore, 27% of participants reported difficulty with speaking. Disease duration (odds ratio [OR] = 1.11) and postswallow residue (OR = 4.03) predicted aspirators (Kroon et al., 2020). An alternative study re­ported manometric changes including simultaneous contractions, incomplete LES relaxation, and impaired UES pres­sures (Yamashita, 2021). These findings may assist in targeted treatment plan­ning, particularly in determining tim­ing of cricopharyngeal intervention, as early intervention may prevent pharyn­geal dilatation and failure, formation of hypopharyngeal pseudodiverticula, or respiratory complications. DSS is cru­cial in evaluating pharyngeal phase dysfunction, particularly pharyngeal
weakness through the validated pha­ryngeal constriction ratio.
In OPMD, the cricopharyngeus muscle dysfunction may be targeted through behavioral therapy, balloon dilation, botulinum toxin injection, and cricopharyngeal myotomy. Manjaly et al. (2011) reviewed nine patients with OPMD treated by repeat bougienage. The average number of dilatations per patient was seven. All patients reported subjective improvement in swallow disability (as measured by the Sydney Swallowing Questionnaire) and there were no adverse reactions to dilatation. Novel treatment of autologous myo­blast transplantation to the CP muscle has shown promising results in Phase I trials, and further results are awaited (Yamashita, 2021).
Myotonic Dystrophy
Myotonic dystrophy (DM1) is the most common inherited muscular dystro­phy worldwide and can begin at any age. It is characterized by myotonia or prolonged muscle contractions, fatigue, and progressive muscle wast­ing and weakness. The disease affects multiple systems, including cardiac and pulmonary, but also endocrine and cognitive functioning, gastrointestinal symptoms, and even cataracts (Wood et al., 2017). A repeat expansion of triplet CTG in the dystrophia myotonia-protein kinase (DMPK) gene on chromosome 19 is responsible (Wood et al., 2017). Asevere congenital form (CDM) results in hypotonia at birth, respiratory fail­ure, and difficulty sucking and swal­lowing (Berggren et al., 2018).
All forms of DM1 are associated with dysphagia (25%–80%). The UK
Соседние файлы в папке @xirurgi_2025